查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496017

全球疼痛管理设备市场 - 2024 年至 2029 年预测

Global Pain Management Devices Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

疼痛管理设备市场预计将从2022年的58.43亿美元增加至2029年的132.17亿美元，年复合成长率为12.38%。

慢性病的增加和老年人口的增加是影响疼痛管理设备市场的主要因素。疼痛管理采用药物和设备的精确组合。疼痛管理装置包括经皮电神经触发器、神经触发器、无痛混合虹吸管和射频消融器。这些设备大多会阻塞疼痛的入口点，阻止疼痛讯号到达大脑。

射频消融器产生热量来杀死神经并阻断疼痛讯号。同样，神经触发装置利用中频电流来破坏疼痛讯号的侵入。这些设备可以帮助治疗独特的疼痛状况，例如恶性生长、肌肉骨骼损伤和神经病变疼痛。疼痛管理装置有助于减少长期镇静剂、非类固醇镇静剂和其他止痛药物的威胁。

美国疾病管制与预防中心估计，美国有 5,000 万人每天承受着持续的慢性疼痛，其中包括 1,960 万名成年人，他们患有严重的疼痛，影响了他们的日常生活或职业。性疼痛。这增加了一些国家的医疗负担。

随着技术、穿戴式装置和小工具越来越融入客户的日常生活，消费者对这些产品的兴趣从新颖性转向更广泛使用的疼痛管理技术，疼痛管理设备市场变得越来越有吸引力。

市场驱动因素：

  • 老年人口的增加预计将推动市场成长。

由于更好的医疗设施和更少的战争，全世界的预期寿命正在增加。随着人们寿命的延长，疼痛发生的频率也会增加，因此越来越需要预防和缓解这种不适。

65岁及以上老年人数量的增加预计将有助于疼痛管理设备市场的扩大。根据世界银行预测，2021年，9.54%的人口将超过65岁。此外，根据联合国（UN）统计《2019年世界人口展望》，未来30年，世界人口预计将从2019年的77亿增加到2050年的97亿，世界人口老化将会加剧。 。因此，随着老年人口的增加，他们将患有慢性背痛和关节炎，导致市场的上升。例如，2023年12月，SPR Therapeutics完成了SPRINT® PNS系统治疗慢性下背痛（LBP）的RESET临床试验註册。本研究将比较经皮週边神经刺激 (PNS) 与慢性下背痛的标准介入治疗。

外科手术数量的增加正在推动市场的成长。

疼痛管理设备市场完全是由外科手术的兴起所推动的。癌症和神经系统问题等长期疾病的发生率不断上升，增加了对手术的需求，从而增加了对缓解疼痛创新的需求。由于技术的进步和微创方法的出现，对疼痛管理设备的需求也在扩大。

此外，疾病早期发现和早期治疗的新兴市场的开拓、公民医疗保健管理意识的提高、获得医疗保健服务的机会的增加以及政府加强医疗保健计划的增加也将推动该市场的发展。

市场限制：

  • 使用止痛药作为疼痛管理主要方法相关的副作用

止痛药通常是治疗的首选药物，因为它们可能有中毒、嗜睡、便秘和噁心等副作用。成瘾药物会使情况更加复杂。其他疼痛管理方法，例如疼痛管理设备，可以在不使用药物的情况下减轻疼痛。这些设备可以与物理治疗结合或作为独立治疗，以减少副作用并改善疼痛管理。

预计北美将占据市场占有率。

由于医疗保健行业的扩张、医疗保健领域的大量投资、创新技术、慢性疼痛发病率上升、环境法规以及全球健康原因（包括易于获得护理管理），北美在疼痛管理设备市场中占据着重要地位。美国也以其先进的医疗基础设施和注重技术进步而闻名。

例如，2023年9月，美国医疗设备製造商波士顿科学公司（Boston Scientific）开发并商业化了治疗异位疼痛（一种慢性下背痛）的Intracept®骨内神经消融系统，并宣布达成收购Relievant Medsystems, Inc.的协议。该交易包括 8.5 亿美元的预付款以及根据未来三年销售业绩支付的额外成功费用。 Intercept System 是唯一获得美国食品药物管理局(FDA) 批准的异位疼痛治疗系统，该系统使用定向射频能源以微创、无植入的门诊手术实现功能改善并提供长期疼痛缓解。

由于衰老和生活方式差异而导致的持续性疼痛的普遍存在可能会推动北美对疼痛治疗设备的需求增加。北美（尤其是美国）的管理方案支持医疗设备的进步、核准和商业化，以控制疼痛并促进创新和扩张。医疗保健服务的便利性有助于提高疼痛管理设备的采用率。

主要进展

  • 2024 年 4 月 -Medtronic)的 Inceptiv(TM) 获得 FDA核准，这是一种用于治疗慢性疼痛的封闭回路型脊髓刺激设备。Medtronic首款具有闭合迴路功能的 SCS，该设备根据脊髓生物讯号自动即时调整刺激，确保治疗与日常生活活动同步。
  • 2023 年 12 月 - Nextim 收到一家经销商公司的两套 NBS 6 系统订单。该系统现在更易于使用，并已在美国和欧盟被核准用于治疗重度忧郁症(MDD)，在欧盟被批准用于治疗慢性神经病变疼痛。
  • 2023 年 8 月 - Zynex, Inc. 推出三种新的疼痛管理治疗产品。第一个是 Zynex Pro 胸腰骶矫正器具，局部是一种用于脊椎的多功能背部矫正器具；第二个是 Zynex Pro 腕部矫正器具，用于治疗手腕相关的疼痛，包括腕管综合症；在家或医院使用。
  • 2023 年 1 月 - 领先的 RPM 和虚拟健康公司 CoachCare 收购了金额位于温斯顿塞勒姆的 NVOLVE，并扩大了其在南卡罗来纳州、北卡罗来纳州、乔治亚、德克萨斯州和田纳西州的投资组合，增加了NVOLVE 的疼痛、脊椎和维吉尼亚整形外科知识。 FCA Venture Partners 是一家创投公司，投资于早期医疗保健技术和技术支援的服务公司，而 CoachCare 是一家总部位于纽约的远端患者监护和虚拟健康公司，提供完整的 RPM 支援服务。
  • 2022 年 8 月 - Abbott 的 Proclaim(TM) Plus 脊髓刺激系统获得 FDA核准，该系统可针对多个疼痛部位提供量身定制的缓解方案，并增加引发疼痛的治疗选择。 FlexBurst360 疗法是 Abbott 专有的 BurstDR™ 刺激的下一代，可根据患者治疗需求的变化进行调整。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球疼痛管理设备市场：依设备分类

  • 介绍
  • 电刺激设备
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 神经刺激设备
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 止痛输液泵
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 消融装置
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球疼痛管理设备市场：依应用分类

  • 介绍
  • 脸部和偏头痛
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 神经病变疼痛
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 癌症痛
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肌肉骨骼疼痛
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球疼痛管理设备市场：按地区

  • 介绍
  • 北美洲
    • 按设备
    • 按用途
    • 按国家/地区
  • 南美洲
    • 按设备
    • 按用途
    • 按国家/地区
  • 欧洲
    • 按设备
    • 按用途
    • 按国家/地区
  • 中东/非洲
    • 按设备
    • 按用途
    • 按国家/地区
  • 亚太地区
    • 按设备
    • 按用途
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • NeuroMetrix, Inc.
  • Medtronic
  • Boston Scientific Corporation
  • Zynex Medical
  • BioElectronics Corporation
  • Pain Management Technologies
  • SPR Therapeutics
  • Becton, Dickinson, and Company
  • Abbott
  • Nevro Corp
简介目录
Product Code: KSI061611753

The global pain management devices market is projected to witness a compounded annual growth rate of 12.38% to reach US$13.217 billion by 2029, up from US$5.843 billion in 2022.

Rising chronic diseases and the geriatric population are the key factors influencing the global pain management devices market. To manage pain, a precise combination of medicines or equipment is used. Pain management devices include transcutaneous electrical nerve triggers, neuro-triggers, the absence of pain mixture siphons, and radiofrequency ablators. A large portion of these devices blocks the pain entryway component to impede the section of pain signs to the mind.

Radiofrequency ablators obliterate nerves by creating warmth to impede the pain signals. Similarly, neuro-trigger devices utilize gentle frequencies of current to obstruct the entry of pain signals. These devices offer assistance in treating distinctive painful conditions like the growth of malignant, musculoskeletal damage, and neuropathic torment. Pain management instruments offer assistance to diminish the threat of long-haul sedatives, non-steroidal calming drugs, and other pain-mitigating medicines.

The Centers for Disease Control and Prevention evaluated that 50 million people within the US endure persistent and chronic daily pain, with adults accounting for 19.6 million that have high-impact chronic and unremitting pain that meddling with their capacity to live their day-to-day lives or their occupations. This is adding to the health care burden of several countries.

The market for pain management devices is appealing as technology, wearables, and gadgets become more integrated into customers' daily lives, and consumer interest in these products shifts from novelty to more widely used pain management techniques.

Market Driver:

  • The growing geriatric population is anticipated to surge the market growth.

People are living longer than ever before worldwide owing to better healthcare facilities and fewer wars. Longer lifespans correspond to a higher occurrence of pain; thus, there is an increasing need to prevent and reduce this discomfort.

The rising number of individuals that over 65 is anticipated to contribute to the pain management devices market expansion. According to the World Bank, in 2021, 9.54% of the population was above 65 years of age. Further, as per the United Nations (UN) statistics for World Population Prospects 2019, the world population is anticipated to rise in the next 30 years, from 7.7 billion in the year 2019 to 9.7 billion in 2050, and the global elderly population is also rising. Thus, with rising elderly population suffers from chronic back pain and arthritis which will lead to a rise in the market. For instance, in December 2023, SPR Therapeutics completed enrollment in the RESET Clinical Trial of the SPRINT(R) PNS System for chronic low back pain (LBP), the largest prospective, multicenter randomized controlled trial to date. The trial compares percutaneous peripheral nerve stimulation (PNS) with standard interventional treatments for chronic LBP.

Increasing the number of surgical procedures carried out will bolster the market growth.

The market for pain management devices is being driven altogether by the rise in surgical operations. The rising rate of long-term sicknesses such as cancer and neurological issues has raised the requirement for surgical methods, which has, in turn, raised the requirement for pain alleviation innovation. The requirement for pain management instruments has also been extended by progresses in innovation and the appearance of negligibly intrusive methods.

Also, it is expected that the market will rise due to the developing accentuation on early illness discovery and treatment, rising awareness of healthcare management among the public, growing healthcare services access, and an increase in government programs to bolster healthcare, will drive the market.

Market Restraints:

  • Side effects associated with using painkillers as a first resort for pain management

Pain medications are frequently the primary line of treatment due to potential side effects such as sickness, drowsiness, constipation, and nausea. Addictive medications can further complicate the situation. Alternative pain management methods, such as pain management devices, can reduce pain without medication. These devices can be used alongside physical therapy or as standalone treatments, reducing side effects and improving pain management.

North America is expected to dominate the market share.

North America has a significant place in the pain management devices market due to its expansive healthcare sector, prominent investment in healthcare, innovative technology, rising chronic pain incidences, environment regulations, and accessibility to healthcare administrations for all regions. The US is also known for its progressed and advanced infrastructure of healthcare and accentuation on advancement in technology.

For instance, in September 2023, Boston Scientific, a US-based medical device manufacturer, announced an agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that developed and commercialized the Intracept(R) Intraosseous Nerve Ablation System for treating heterogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and additional contingent payments based on sales performance over the next three years. The Intercept system is the only U.S. Food and Drug Administration-cleared system for heterogenic pain, a minimally invasive, implant-free outpatient procedure that uses targeted radiofrequency energy to improve function and provide long-term relief.

The predominance of persistent pain due to an elderly populace and wrong lifestyle issues may drive the rising demand for pain administration devices in North America. The regulatory initiatives in North America, especially the US, assist the advancement, endorsement, and commercialization of medical devices that manage pain, cultivating innovation and expansion. This accessibility to healthcare services contributes to the higher adoption rate of pain management devices.

Key Developments:

  • April 2024- Medtronic received FDA approval for its Inceptiv(TM) closed-loop spinal cord stimulator, which is designed to treat chronic pain. The device, the first Medtronic SCS to offer a closed-loop feature, automatically adjusts stimulation in real-time based on biological signals along the spinal cord, ensuring therapy is in harmony with daily life motions.
  • December 2023- Nexstim received an order for two NBS 6 systems from a distributor company, which are now more user-friendly and approved for treating major depressive disorder (MDD) in the US and EU, as well as chronic neuropathic pain in the EU.
  • August 2023- Zynex, Inc. introduced three new therapy products for pain management. The first is the Zynex Pro Thoracic Lumbar Sacral Orthosis, a dual-purpose back brace for the spine; the second is the Zynex Pro Wrist, a wrist brace for wrist-related pain management, including carpal tunnel syndrome; and the third is the Zynex Cryoheat, a localized fluid therapy system for home or hospital use.
  • January 2023- CoachCare, a leading RPM and virtual health company acquired Winston-Salem-based NVOLVE for an undisclosed amount, adding NVOLVE's expertise in pain, spine, and orthopedic specialties to its services across South Carolina, North Carolina, Georgia, Texas, Tennessee, and Virginia. FCA Venture Partners is a venture capital firm that invests in early-stage healthcare technology and technology-enabled services companies, while CoachCare, a New York-based remote patient monitoring and virtual health company, offers complete RPM support services.
  • August 2022- Abbott received FDA approval for its Proclaim(TM) Plus spinal cord stimulation system, which offers tailored relief to multiple painful areas and offers more treatment options for evoking pain conditions. The FlexBurst360 therapy, the next generation of Abbott's proprietary BurstDR(TM) stimulation, can be adjusted as a person's therapeutic needs evolve.

Market Segmentation:

Global Pain Management Devices Market is segmented and analyzed as below:

By Devices

  • Electrical Stimulators
  • Neurostimulation Devices
  • Analgesic Infusion Pumps
  • Ablation Devices

By Application

  • Facial & Migraine Pain
  • Neuropathic Pain
  • Cancer Pain
  • Musculoskeletal Pain
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • Italy
  • France
  • Others
  • Middle East and Africa
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY DEVICES

  • 5.1. Introduction
  • 5.2. Electrical Stimulators
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Neurostimulation Devices
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Analgesic Infusion Pumps
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Ablation Devices
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Facial & Migraine Pain
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Neuropathic Pain
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Cancer Pain
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 6.5. Musculoskeletal Pain
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Devices
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Devices
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Devices
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. UK
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. Italy
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. France
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Others
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Devices
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Israel
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. Saudi Arabia
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Devices
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. Australia
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. South Korea
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Taiwan
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Thailand
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Indonesia
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects
      • 7.6.3.9. Others
        • 7.6.3.9.1. Market Opportunities and Trends
        • 7.6.3.9.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. NeuroMetrix, Inc.
  • 9.2. Medtronic
  • 9.3. Boston Scientific Corporation
  • 9.4. Zynex Medical
  • 9.5. BioElectronics Corporation
  • 9.6. Pain Management Technologies
  • 9.7. SPR Therapeutics
  • 9.8. Becton, Dickinson, and Company
  • 9.9. Abbott
  • 9.10. Nevro Corp